Catalyst Brief

← Calendar

Readoutin 165d

Sanofi — Frexalimab

Phase 3 primary completion: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis.

Date
May 2027
Type
Readout
Indication
Multiple Sclerosis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sanofi

  1. Apr2027
    Readoutin 135d
    Sanofi — Isatuximab SAR650984
    Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant.
  2. Nov2026